TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business. During the quarter, the company advanced its main asset, EB06, an anti-CXCL10 monoclonal antibody candidate being developed for the effective and durable treatment of vitiligo. Preparation for the manufacturing campaign is underway, with data anticipated to be submitted to regulators at the U.S. Food and Drug Administration (FDA) during the middle of 2025. The company in

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa's CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred shares ("Series B-1 Preferred Shares") and 3,468,746 common shares in a private placement priced at-the-market under the rules

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project f

HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

4 - Edesa Biotech, Inc. (0001540159) (Issuer)

4 - Edesa Biotech, Inc. (0001540159) (Issuer)

3 - Edesa Biotech, Inc. (0001540159) (Issuer)

4 - Edesa Biotech, Inc. (0001540159) (Issuer)

EFFECT - Edesa Biotech, Inc. (0001540159) (Filer)

424B3 - Edesa Biotech, Inc. (0001540159) (Filer)

S-3 - Edesa Biotech, Inc. (0001540159) (Filer)

TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturing activities.Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry, Manufacturing and Controls (CMC) in the biopharmaceutical field and will lead the company's strategic planning and operations related to scale-up, manufacturing and quality control."We are pleased to welcome Raj to our management team in anticipation o

SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)